［1］ LOPEZ-BELTRAN A,COOKSON MS,GUERCIO BJ,et al.Advances in diagnosis and treatment of bladder cancer［J］.BMJ,2024,384:e076743.
［2］ VAN HOOGSTRATEN LMC,VRIELING A,VAN DER HEIJDEN AG,et al.Global trends in the epidemiology of bladder cancer:challenges for public health and clinical practice［J］.Nat Rev Clin Oncol,2023,20(5):287-304.
［3］ ZHAO J,LI J,ZHANG R.Off the fog to find the optimal choice:Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer［J］.Biochim Biophys Acta Rev Cancer,2023,1878(4):188926.
［4］ BABJUK M,BURGER M,CAPOUN O,et al.European association of urology guidelines on non-muscle-invasive bladder cancer (Ta,T1,and carcinoma in situ)［J］.Eur Urol,2022,81(1):75-94.
［5］ MANDEL P,METAIS P.Nuclear acids in human blood plasma［J］.C R Seances Soc Biol Fil,1948,142(3-4):241-243.
［6］ MAIA MC,SALGIA M,PAL SK.Harnessing cell-free DNA:plasma circulating tumour DNA for liquid biopsy in genitourinary cancers［J］.Nat Rev Urol,2020,17(5):271-291.
［7］ DANG DK,PARK BH.Circulating tumor DNA:current challenges for clinical utility［J］.J Clin Invest,2022,132(12):e154941.
［8］ TODENHOFER T,STRUSS WJ,SEILER R,et al.Liquid biopsy-analysis of circulating tumor DNA (ctDNA) in bladder cancer［J］.Bladder Cancer,2018,4(1):19-29.
［9］ PASCUAL J,ATTARD G,BIDARD FC,et al.ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer:a report from the ESMO Precision Medicine Working Group［J］.Ann Oncol,2022,33(8):750-768.
［10］ MOULIERE F,CHANDRANANDA D,PISKORZ AM,et al.Enhanced detection of circulating tumor DNA by fragment size analysis［J］.Sci Transl Med,2018,10(466):eaat4921.
［11］ UNDERHILL HR,KITZMAN JO,HELLWIG S,et al.Fragment length of circulating tumor DNA［J］.PLoS Genet,2016,12(7):e1006162.
［12］ CHEN X,WANG L,LOU J.Nanotechnology strategies for the analysis of circulating tumor DNA:A review［J］.Med Sci Monit,2020,26:e921040.
［13］ RINK M,SCHWARZENBACH H,RIETHDORF S,et al.The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder［J］.World J Urol,2019,37(9):1785-1799.
［14］ VANDEKERKHOVE G,TODENHOFER T,ANNALA M,et al.Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer［J］.Clin Cancer Res,2017,23(21):6487-6497.
［15］ WAN JCM,MASSIE C,GARCIA-CORBACHO J,et al.Liquid biopsies come of age:towards implementation of circulating tumour DNA［J］.Nat Rev Cancer,2017,17(4):223-238.
［16］ ULZ P,THALLINGER GG,AUER M,et al.Inferring expressed genes by whole-genome sequencing of plasma DNA［J］.Nat Genet,2016,48(10):1273-1278.
［17］ CHENG ML,PECTASIDES E,HANNA GJ,et al.Circulating tumor DNA in advanced solid tumors:Clinical relevance and future directions［J］.CA Cancer J Clin,2021,71(2):176-190.
［18］ PELLINI B,CHAUDHURI AA.ctDNA monitoring for small cell lung cancer:Ready for prime time［J］.Clin Cancer Res,2023,29(12):2176-2178.
［19］ SANTONJA A,COOPER WN,ELDRIDGE MD,et al.Comparison of tumor-informed and tumor-naive sequencing assays for ctDNA detection in breast cancer［J］.EMBO Mol Med,2023,15(6):e16505.
［20］ MO S,YE L,WANG D,et al.Early detection of molecular residual disease and risk stratification for stage Ⅰto Ⅲ colorectal cancer via circulating tumor DNA methylation［J］.JAMA Oncol,2023,9(6):770-778.
［21］ HUEBNER A,BLACK JRM,SARNO F,et al.ACT-discover:identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA［J］.Genome Med,2023,15(1):27.
［22］ 单逸凡,戴一扬.循环肿瘤DNA在胃癌和结直肠癌早期诊断中的应用进展［J］.现代肿瘤医学，2024，32（15）：2915-2920.
SHAN YF,DAI YY.Application progress of circulating tumor DNA in early diagnosis of gastric cancer and colorectal cancer［J］.Modern Oncology,2024，32（15）：2915-2920.
［23］ 喻明,苏亚娟.循环肿瘤DNA甲基化在卵巢癌中的研究进展［J］.现代肿瘤医学，2022,30(19):3611-3614.
YU M,SU YJ.Research progress of circulating tumor DNA methylation in ovarian cancer［J］.Modern Oncology,2022,30(19):3611-3614.
［24］ PALACIN-ALIANA I,GARCIA-ROMERO N,ASENSI-PUIG A,et al.Clinical utility of liquid biopsy-based actionable mutations detected via ddPCR［J］.Biomedicines,2021,9(8):906.
［25］ PENG R,ZHANG R,LI J.Continual improvement of the reliability of next-generation sequencing-based ctDNA analysis:A long-term comparison of ctDNA detection in China［J］.Clin Chem,2022,68(7):940-952.
［26］ MOSELE F,REMON J,MATEO J,et al.Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers:a report from the ESMO Precision Medicine Working Group［J］.Ann Oncol,2020,31(11):1491-1505.
［27］ 辇伟奇,于津浦,袁响林,等.ctDNA高通量测序临床实践专家共识（2022年版）［J］.中国癌症防治杂志,2022,14(03):240-252.
YAN WQ,YU JP,YUAN XL,et al.Expert consensus on clinical practice of ctDNA high-throughput sequencing (2022 edition)［J］.Chin J Cancer Prevention and Treatment,2022,14(03):240-252.
［28］ RANUCCI R.Cell-free DNA:Applications in different diseases［J］.Methods Mol Biol,2019,1909:3-12.
［29］ CHRISTENSEN E,WYATT AW,GALSKY MD,et al.IBCN seminar series 2021:Circulating tumor DNA in bladder cancer［J］.Urol Oncol,2022,41(7):318-322.
［30］ GORMALLY E,VINEIS P,MATULLO G,et al.TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence:a prospective study［J］.Cancer Res,2006,66(13):6871-6876.
［31］ HOSEN MI,SHEIKH M,ZVEREVA M,et al.Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer:Evidence from the golestan cohort study［J］.EBioMedicine,2020,53:102643.
［32］ GREEN EA,LI R,ALBIGES L,et al.Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer:A critical review of current literature［J］.Eur Urol Oncol,2021,4(6):893-903.
［33］ KLEIN EA,RICHARDS D,COHN A,et al.Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set［J］.Ann Oncol,2021,32(9):1167-1177.
［34］ DUDLEY JC,SCHROERS-MARTIN J,LAZZARESCHI DV,et al.Detection and surveillance of bladder cancer using urine tumor DNA［J］.Cancer Discovery,2019,9(4):500-509.
［35］ ZHANG J,DAI D,TIAN J,et al.Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer［J］.Front Oncol,2021,11:657483.
［36］ 杨孝杰,高中伟,任小强,等.尿液中循环肿瘤DNA水平预测非肌层浸润性膀胱癌术后复发及进展的临床价值［J］.现代肿瘤医学,2022,30(11):1994-1997.
YANG XJ,GAO ZW,REN XQ,et al.Clinical value of urinary circulating tumor DNA level in predicting postoperative recurrence and progression of non-muscle invasive bladder cancer［J］.Modern Oncology,2022,30(11):1994-1997.
［37］ CARRASCO R,INGELMO-TORRES M,GOMEZ A,et al.Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer［J］.Int J Mol Sci,2022,23(19):11732.
［38］ SHOHDY KS,VILLAMAR DM,CAO Y,et al.Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma［J］.Br J Cancer,2022,126(3):430-439.
［39］ CHALFIN HJ,GLAVARIS SA,GORIN MA,et al.Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer［J］.Eur Urol Oncol,2021,4(2):310-314.
［40］ VIVANCOS A,TABERNERO J.Circulating tumor DNA as a novel prognostic indicator［J］.Nat Med,2022,28(11):2255-2256.
［41］ CRUPI E,DE PADUA TC,MARANDINO L,et al.Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer:A systematic review［J］.Eur Urol Oncol,2024,7(1):44-52.
［42］ LINDSKROG SV,LALIOTIS G,BIRKENKAMP-DEMTRODER K,et al.Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients［J］.Cancer Research,2023,83(7_suppl):5600.
［43］ LARS D,GEORGE LALIOTIS MDP,IVER N,et al.Utility of ctDNA in predicting outcome and pathological complete response in patients with bladder cancer as a guide for selective bladder preservation strategies［J］.Journal of Clinical Oncology,2023,41(6_suppl):563.
［44］ LAUKHTINA E,HASSLER MR,PRADERE B,et al.Circulating tumour DNA is a strong predictor of outcomes in patients treated with systemic therapy for urothelial carcinoma［J］.Eur Urol Focus,2022,8(6):1683-1686.
［45］ VANDEKERKHOVE G,LAVOIE JM,ANNALA M,et al.Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer［J］.Nat Commun,2021,12(1):184.
［46］ ABURUSTUM N,YASHAR C,AREND R,et al.Uterine neoplasms,version 1.2023,NCCN clinical practice guidelines in oncology［J］.Journal of the National Comprehensive Cancer Network,2023,21(2):181-209.
［47］ TIE J,COHEN JD,LAHOUEL K,et al.Circulating tumor DNA analysis guiding adjuvant therapy in stage Ⅱ colon cancer［J］.N Engl J Med,2022,386(24):2261-2272.
［48］ TIVEY A,CHURCH M,ROTHWELL D,et al.Circulating tumour DNA-looking beyond the blood［J］.Nat Rev Clin Oncol,2022,19(9):600-612.
［49］ CHAUHAN PS,SHIANG A,ALAHI I,et al.Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients［J］.NPJ Precis Oncol,2023,7(1):6.
［50］ CHAUHAN PS,CHEN K,BABBRA RK,et al.Correction:Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy:A cohort study［J］.PLoS Med,2021,18(12):e1003876.
［51］ CHRISTENSEN E,BIRKENKAMP-DEMTRODER K,SETHI H,et al.Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma［J］.J Clin Oncol,2019,37(18):1547-1557.
［52］ BIRKENKAMP-DEMTRODER K,NORDENTOFT I,CHRISTENSEN E,et al.Genomic alterations in liquid biopsies from patients with bladder cancer［J］.Eur Urol,2016,70(1):75-82.
［53］ POWLES T,ASSAF ZJ,DAVARPANAH N,et al.ctDNA guiding adjuvant immunotherapy in urothelial carcinoma［J］.Nature,2021,595(7867):432-437.
［54］ SZABADOS B,KOCKX M,ASSAF ZJ,et al.Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder［J］.Eur Urol,2022,82(2):212-222.
［55］ JACKSON-SPENCE F,TOMS C,O' MAHONY LF,et al.IMvigor011:a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery［J］.Future Oncol,2023,19(7):509-515.
［56］ BRATMAN SV,YANG SYC,IAFOLLA MAJ,et al.Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab［J］.Nat Cancer,2020,1(9):873-881.
［57］ ROSENBERG JE,HOFFMAN-CENSITS J,POWLES T,et al.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm,multicentre,phase 2 trial［J］.Lancet,2016,387(10031):1909-1920.